{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:20:28Z","timestamp":1789669228484,"version":"4.0.1"},"reference-count":48,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Resistance to cytotoxic drugs frequently emerges during treatment of leukemia with conventional chemotherapy. New classes of anticancer drugs, such as the farnesyltransferase inhibitors (FTIs), show therapeutic promise, but whether cells will easily develop resistance against them is not known. Here, we grew breakpoint cluster region\/Abelson murine leukemia (Bcr\/Abl) P190 lymphoblasts on stroma and made them resistant to the FTI SCH66336\/lonafarnib to model emerging drug resistance in a patient. These cells exhibited greatly increased (&amp;gt; 100-fold) expression levels of a novel ATP (adenosine triphosphate)-binding cassette (ABC) transporter-homologous gene, ATP11A. We showed that overexpression of this gene provided protection against the effects of SCH66336, whereas knockdown of endogenous ATP11a using small interfering RNA (siRNA) made cells more sensitive to this drug. The lymphoblasts that were resistant to this FTI were also more resistant to FTI-276 and to GGTI-298, 2 other structurally similar inhibitors. Surprisingly, the cells were also able to survive higher concentrations of imatinib mesylate, the Bcr\/Abl tyrosine kinase inhibitor. However, the cells remained sensitive to vincristine. Our results show that elevated levels of ATP11a can protect malignant lymphoblastic leukemia cells against several novel small molecule signal transduction inhibitors. A determination of the expression levels of this gene may have prognostic value when treatment with such classes of drugs is contemplated. (Blood. 2005;106: 1355-1361)<\/jats:p>","DOI":"10.1182\/blood-2004-09-3655","type":"journal-article","created":{"date-parts":[[2005,4,29]],"date-time":"2005-04-29T00:34:27Z","timestamp":1114734867000},"page":"1355-1361","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":28,"title":["Resistance to farnesyltransferase inhibitors in Bcr\/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a"],"prefix":"10.1182","volume":"106","author":[{"given":"Bin","family":"Zhang","sequence":"first","affiliation":[{"name":"From the Section of Molecular Carcinogenesis, Division of Hematology\/Oncology, Childrens Hospital Los Angeles Saban Research Institute, Los Angeles, CA; and the Keck School of Medicine, University of Southern California, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Groffen","sequence":"additional","affiliation":[{"name":"From the Section of Molecular Carcinogenesis, Division of Hematology\/Oncology, Childrens Hospital Los Angeles Saban Research Institute, Los Angeles, CA; and the Keck School of Medicine, University of Southern California, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Heisterkamp","sequence":"additional","affiliation":[{"name":"From the Section of Molecular Carcinogenesis, Division of Hematology\/Oncology, Childrens Hospital Los Angeles Saban Research Institute, Los Angeles, CA; and the Keck School of Medicine, University of Southern California, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021222105990000_REF1","unstructured":"Heisterkamp N, Groffen J. BCR\/ABL gene structure and BCR function. In: Carella AM, Daley GQ, Eaves CM, Goldman JM, Hehlman R, eds. Chronic Myeloid Leukemia: Biology and Treatment. Oxford, United Kingdom: Martin Dunitz Ltd; 2001: 3-17."},{"key":"2020021222105990000_REF2","doi-asserted-by":"crossref","unstructured":"Goldman JM, Melo JV. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med.2003;349: 1451-1464.","DOI":"10.1056\/NEJMra020777"},{"key":"2020021222105990000_REF3","doi-asserted-by":"crossref","unstructured":"Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med.2000;342: 998-1006.","DOI":"10.1056\/NEJM200004063421402"},{"key":"2020021222105990000_","doi-asserted-by":"crossref","unstructured":"Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 trial. Blood.2002;100: 2357-2366.","DOI":"10.1182\/blood-2002-03-0704"},{"key":"2020021222105990000_REF5","doi-asserted-by":"crossref","unstructured":"Faderl S, Garcia-Manero G, Thomas DA, Kantarjian HM. Philadelphia chromosome-positive acute lymphoblastic leukemia: current concepts and future perspectives. Rev Clin Exp Hematol.2002;6: 142-160.","DOI":"10.1046\/j.1468-0734.2002.00066.x"},{"key":"2020021222105990000_REF6","doi-asserted-by":"crossref","unstructured":"Hoelzer D, Gokbuget N, Ottmann OG. Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Semin Hematol.2002;39: 32-37.","DOI":"10.1053\/shem.2002.36927"},{"key":"2020021222105990000_REF7","doi-asserted-by":"crossref","unstructured":"Schiffer CA, Hehlmann R, Larson R. Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL. Leukemia.2003;17: 691-699.","DOI":"10.1038\/sj.leu.2402879"},{"key":"2020021222105990000_REF8","doi-asserted-by":"crossref","unstructured":"Cortes J, Kantarjian H. Advanced-phase chronic myeloid leukemia. Semin Hematol.2003;40: 79-86.","DOI":"10.1016\/S0037-1963(03)70045-6"},{"key":"2020021222105990000_","doi-asserted-by":"crossref","unstructured":"Holtz MS, Bhatia R. Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells. Leuk Lymphoma.2004;45: 237-245.","DOI":"10.1080\/1042819031000151905"},{"key":"2020021222105990000_REF10","doi-asserted-by":"crossref","unstructured":"Tipping AJ, Baluch S, Barnes DJ, et al. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. Leukemia.2004;18: 1352-1356.","DOI":"10.1038\/sj.leu.2403416"},{"key":"2020021222105990000_REF11","doi-asserted-by":"crossref","unstructured":"Mishra S, Zhang B, Groffen J, Heisterkamp N. Treatment of advanced P190 Bcr\/Abl positive leukemia with a farnesyltransferase inhibitor. Leukemia.2004;18: 23-28.","DOI":"10.1038\/sj.leu.2403203"},{"key":"2020021222105990000_REF12","doi-asserted-by":"crossref","unstructured":"Peters DG, Hoover RR, Gerlach MJ, et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR\/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood.2001;97: 1404-1412.","DOI":"10.1182\/blood.V97.5.1404"},{"key":"2020021222105990000_REF13","doi-asserted-by":"crossref","unstructured":"Reichert A, Heisterkamp N, Daley GQ, Groffen J. Treatment of Bcr\/Abl-positive ALL in P190 transgenic mice with the farnesyltransferase inhibitor SCH66336. Blood.2001;97: 399-1403.","DOI":"10.1182\/blood.V97.5.1399"},{"key":"2020021222105990000_REF14","doi-asserted-by":"crossref","unstructured":"Brodsky AL. Apoptotic synergism between STI571 and the farnesyl transferase inhibitor SCH66336 on an imatinib-sensitive cell line. Blood.2003;101: 2070-2071.","DOI":"10.1182\/blood-2002-09-2980"},{"key":"2020021222105990000_","doi-asserted-by":"crossref","unstructured":"Daley GQ. Towards combination target-directed chemotherapy for chronic myeloid leukemia: role of farnesyl transferase inhibitors. Semin Hematol.2003;40: 11-14.","DOI":"10.1053\/shem.2003.50035"},{"key":"2020021222105990000_","doi-asserted-by":"crossref","unstructured":"Hoover RR, Mahon FX, Melo JV, Daley GQ. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood.2002;100: 1068-1071.","DOI":"10.1182\/blood.V100.3.1068"},{"key":"2020021222105990000_REF17","unstructured":"Nakajima A, Tauchi T, Sumi M, Bishop WR, Ohyashiki K. Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. Mol Cancer Ther.2003;2: 219-224."},{"key":"2020021222105990000_REF18","doi-asserted-by":"crossref","unstructured":"Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol.2004;11: 35-43.","DOI":"10.1097\/00062752-200401000-00006"},{"key":"2020021222105990000_REF19","doi-asserted-by":"crossref","unstructured":"Weisbeg E, Griffin JD. Resistance to Imatinib (Glivec): update on clinical mechanisms. Drug Resist Update.2003;6: 231-238.","DOI":"10.1016\/S1368-7646(03)00062-1"},{"key":"2020021222105990000_REF20","doi-asserted-by":"crossref","unstructured":"Jabbour E, Kantarjian H, Cortes J. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk Lymphoma.2004;45: 2187-2195.","DOI":"10.1080\/10428190412331272677"},{"key":"2020021222105990000_","unstructured":"Karp JE, Lancet JE. Farnesyltransferase inhibitors (FTIs) in myeloid malignancies. Ann Hematol.2004;83(suppl 1): S87-S88."},{"key":"2020021222105990000_","doi-asserted-by":"crossref","unstructured":"Russo P, Loprevite M, Cesario A, Ardizzoni A. Farnesylated proteins as anticancer drug targets: from laboratory to the clinic. Curr Med Chem Anti-Canc Agents.2004;4: 123-138.","DOI":"10.2174\/1568011043482098"},{"key":"2020021222105990000_REF23","unstructured":"Zhu K, Hamilton AD, Sebti SM. Farnesyltransferase inhibitors as anticancer agents: current status. Curr Opin Investig Drugs.2003;12: 1428-1435."},{"key":"2020021222105990000_REF24","unstructured":"Voncken J-W, Griffiths S, Greaves MF, Pattengale PK, Heisterkamp N, Groffen J. Restricted oncogenicity of BCR\/ABL P190 in transgenic mice. Cancer Res.1992;52: 4534-4539."},{"key":"2020021222105990000_REF25","doi-asserted-by":"crossref","unstructured":"Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukemia in BCR\/ABL transgenic mice. Nature.1990;344: 251-254.","DOI":"10.1038\/344251a0"},{"key":"2020021222105990000_REF26","doi-asserted-by":"crossref","unstructured":"Schageman JJ, Horton CJ, Niu S, Garner HR, Pertsemlidis A. ELXR: a resource for rapid exon-directed sequence analysis. Genome Biol.2004;5: R36.","DOI":"10.1186\/gb-2004-5-5-r36"},{"key":"2020021222105990000_REF27","doi-asserted-by":"crossref","unstructured":"Goda SK, Minton NP. A simple procedure for gel electrophoresis and Northern blotting of RNA. Nucl Acids Res.1995;23: 3357-3358.","DOI":"10.1093\/nar\/23.16.3357"},{"key":"2020021222105990000_REF28","doi-asserted-by":"crossref","unstructured":"Su YR, Linton MF, Fazio SJ. Rapid quantification of murine ABC mRNAs by real time reverse transcriptase-polymerase chain reaction. Lipid Res.2002;43: 2180-2187.","DOI":"10.1194\/jlr.D200020-JLR200"},{"key":"2020021222105990000_REF29","unstructured":"Weizmann Institute of Science. GeneCards: database of human genes, their products and their involvement in diseases. http:\/\/bioinfo.weizmann.ac.il\/cards\/index.shtml. Accessed on June 10, 2005."},{"key":"2020021222105990000_REF30","doi-asserted-by":"crossref","unstructured":"Del Villar K, Urano J, Guo L, Tamanoi F. A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors. J Biol Chem.1999;274: 27010-27017.","DOI":"10.1074\/jbc.274.38.27010"},{"key":"2020021222105990000_REF31","unstructured":"Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH. Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res.2000;6: 2318-2325."},{"key":"2020021222105990000_REF32","doi-asserted-by":"crossref","unstructured":"Del Villar K, Mitsuzawa H, Yang W, Sattler I, Tamanoi F. Amino acid substitutions that convert the protein substrate specificity of farnesyltransferase to that of geranylgeranyltransferase type I. J Biol Chem.1997;272: 680-687.","DOI":"10.1074\/jbc.272.1.680"},{"key":"2020021222105990000_REF33","doi-asserted-by":"crossref","unstructured":"Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer.2002;2: 48-58.","DOI":"10.1038\/nrc706"},{"key":"2020021222105990000_REF34","doi-asserted-by":"crossref","unstructured":"Halleck MS, Lawler JF Jr, Blackshaw S, et al. Differential expression of putative transbilayer amphipath transporters. Physiol Genomics.1999;1: 139-150.","DOI":"10.1152\/physiolgenomics.1999.1.3.139"},{"key":"2020021222105990000_REF35","doi-asserted-by":"crossref","unstructured":"Ashar HR, James L, Gray K, et al. The farnesyl transferase inhibitor SCH 66336 induces a G(2) \u2014&gt; M or G(1) pause in sensitive human tumor cell lines. Exp Cell Res.2001;262: 17-27.","DOI":"10.1006\/excr.2000.5076"},{"key":"2020021222105990000_REF36","doi-asserted-by":"crossref","unstructured":"Njoroge FG, Taveras AG, Kelly J, et al. (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]-cyclohepta[1,2-b]-pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide(SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent. J Med Chem.1998;41: 4890-4902.","DOI":"10.1021\/jm980462b"},{"key":"2020021222105990000_REF37","doi-asserted-by":"crossref","unstructured":"Roskoski R Jr. Protein prenylation: a pivotal post-translational process. Biochem Biophys Res Commun.2003;303: 1-7.","DOI":"10.1016\/S0006-291X(03)00323-1"},{"key":"2020021222105990000_REF38","doi-asserted-by":"crossref","unstructured":"Morgan MA, Wegner J, Aydilek E, Ganser A, Reuter CW. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors. Leukemia.2003;17: 1508-1520.","DOI":"10.1038\/sj.leu.2403022"},{"key":"2020021222105990000_REF39","unstructured":"van de Donk NW, Schotte D, Kamphuis MM, et al. Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells. Clin Cancer Res.2003;9: 5735-5748."},{"key":"2020021222105990000_REF40","doi-asserted-by":"crossref","unstructured":"Ronghe M, Burke GA, Lowis SP, Estlin EJ. Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines. Cancer Treat Rev.2001;27: 27-37.","DOI":"10.1053\/ctrv.2001.0243"},{"key":"2020021222105990000_REF41","unstructured":"Smith V, Rowlands MG, Barrie E, Workman P, Kelland LR. Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line. Clin Cancer Res.2002;6: 2002-2009."},{"key":"2020021222105990000_REF42","doi-asserted-by":"crossref","unstructured":"Srivastava N. ATP binding cassette transporter A1: key roles in cellular lipid transport and atherosclerosis. Mol Cell Biochem.2002;237: 155-164.","DOI":"10.1023\/A:1016506221047"},{"key":"2020021222105990000_REF43","doi-asserted-by":"crossref","unstructured":"Gan X, Kaplan R, Menke JG, et al. Dual mechanisms of ABCA1 regulation by geranylgeranyl pyrophosphate. J Biol Chem.2001;276: 48702-48708.","DOI":"10.1074\/jbc.M109402200"},{"key":"2020021222105990000_REF44","doi-asserted-by":"crossref","unstructured":"Wang EJ, Johnson WW. The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2. Chemotherapy.2003;49: 303-308.","DOI":"10.1159\/000074531"},{"key":"2020021222105990000_REF45","doi-asserted-by":"crossref","unstructured":"Oude Elferink R, Groen AK. Genetic defects in hepatobiliary transport. Biochim Biophys Acta.2002;1586: 129-145.","DOI":"10.1016\/S0925-4439(01)00103-X"},{"key":"2020021222105990000_REF46","unstructured":"National Center for Biotechnology Information. UniGene: gene-oriented clusters of transcript sequences. http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?db=unigene. Accessed on June 10, 2005."},{"key":"2020021222105990000_REF47","doi-asserted-by":"crossref","unstructured":"Cortes J. Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma.2003;4: S30-S35.","DOI":"10.3816\/CLM.2003.s.006"},{"key":"2020021222105990000_REF48","doi-asserted-by":"crossref","unstructured":"Smalley KS, Eisen TG. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int J Cancer.2003;105: 165-175.","DOI":"10.1002\/ijc.11064"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/4\/1355\/1712575\/zh801605001355.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/4\/1355\/1712575\/zh801605001355.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T04:22:24Z","timestamp":1586233344000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/106\/4\/1355\/21559\/Resistance-to-farnesyltransferase-inhibitors-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,15]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,8,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-09-3655","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,15]]}}}